Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Drugs Today (Barc). 2012 Sep;48(9):601-13. doi: 10.1358/dot.2012.48.9.1869590.

New and established tyrosine kinase inhibitors for chronic myeloid leukemia.

Author information

  • 1University of Colorado School of Medicine, Division of BMT/Hematology, Denver, Colorado, USA.


Chronic myeloid leukemia (CML) is an uncommon malignancy, the treatment and prognosis of which have dramatically shifted over the last decade. Characterized by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, small-molecule tyrosine kinase inhibitors (TKIs) targeted against the oncogenic BCR-ABL fusion protein have changed this once fatal disease into the model of targeted therapy. This article will review the pharmacological and clinical data supporting the use of imatinib and the second-generation TKIs dasatinib and nilotinib, and the novel TKIs bosutinib and ponatinib.

Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk